Infect Chemother.  2013 Dec;45(4):367-374. 10.3947/ic.2013.45.4.367.

Medical Treatment of Pulmonary Multidrug-Resistant Tuberculosis

• Shim TS
• Jo KW

• KMID: 2170440
• DOI: http://doi.org/10.3947/ic.2013.45.4.367

Abstract

Treatment of multidrug-resistant tuberculosis (MDR-TB) is challenging because of the high toxicity of second-line drugs and the longer treatment duration required compared with drug-susceptible TB. The efficacy of treatment for MDR-TB is poorer than that for drug-susceptible TB. The selection of drugs in MDR-TB is based on previous treatment history, drug susceptibility results, and TB drug resistance patterns in the each region. Recent World Health Organization guidelines recommend the use of least 4 second-line drugs (a newer fluoroquinolone, an injectable agent, prothionamide, and cycloserine or para-aminosalicylic acid) in addition to pyrazinamide. The kanamycin is the initial choice of injectable durgs, and newer fluoroquinolones include levofloxacin and moxifloxacin. For MDR-TB, especially cases that are extensively drug-resistant, group 5 drugs such as linezolid, clofazimine, and amoxicillin/clavulanate need to be included. New agents with novel mechanisms of action that can be given for shorter durations (9-12 months) for MDR-TB are under investigation.

Keyword

Tuberculosis; Multidrug-resistant; Therapeutics; Extensively drug-resistant tuberculosis

MeSH Terms

Clofazimine
Cycloserine
Drug Resistance
Extensively Drug-Resistant Tuberculosis
Fluoroquinolones
Kanamycin
Levofloxacin
Linezolid
Prothionamide
Pyrazinamide
Tuberculosis
Tuberculosis, Multidrug-Resistant*
World Health Organization
Clofazimine
Cycloserine
Fluoroquinolones
Kanamycin
Prothionamide
Pyrazinamide

Reference

1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: WHO;2008.

2. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest. 2003; 124:1476–1481.

3. Lee J, Lee CH, Kim DK, Yoon HI, Kim JY, Lee SM, Yang SC, Lee JH, Yoo CG, Lee CT, Chung HS, Kim YW, Han SK, Yim JJ. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. Korean J Intern Med. 2011; 26:153–159.

4. Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, Jang SH, Yoo KH, Jung KH, Kim KU, Choi SB, Ryu YJ, Chan Kim K, Um S, Kwon YS, Kim YH, Choi WI, Jeon K, Hwang YI, Kim SJ, Lee YS, Heo EY, Lee J, Ki YW, Shim TS, Yim JJ. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013; 188:858–864.

5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. Geneva, Switzerland: WHO;2011.

6. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. Geneva, Switzerland: WHO;2008.

7. World Health Organization. The use of molecular line probe assay for the detection of resistnace to second-line anti-tuberculosis drugs. Geneva, Switzerland: WHO;2013.

8. Telenti A. Genetics of drug resistance in tuberculosis. Clin Chest Med. 1997; 18:55–64.

9. Uzun M, Erturan Z, Anğ O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis. 2002; 6:164–165.

10. Lew WJ, Park YK, Kim HJ, Chang C, Bai GH, Kim SK. The Proportion of Rifabutin-susceptible Strains among Rifampicin-resistant Isolates and Its Specific rpoB Mutations. Tuberc Respir Dis. 2005; 59:257–265.

11. Kim BJ, Oh SH, Cho EJ, Park SK. Cross-resistance between rifampicin and rifabutin and its relationship with rpoB gene mutations in clinically isolated MDR-TB strains. Tuberc Respir Dis. 2006; 60:171–179.

12. Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, Hirakata Y, Maesaki S, Tomono K, Tashiro T, Kohno S. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother. 1998; 42:621–628.

13. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998; 42:1853–1857.

14. Jo KW, Ji W, Hong Y, Lee SD, Kim WS, Kim DS, Shim TS. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med. 2013; 107:292–297.

15. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012; 67:819–831.

16. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2012; 67:1088–1093.

17. Xu C, Kreiswirth BN, Sreevatsan S, Musser JM, Drlica K. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis. 1996; 174:1127–1130.

18. Park YK, Park CH, Koh WJ, Kwon OJ, Kim BJ, Kook YH, Cho SN, Chang CH, Bai GH. Cross resistance of fluoroquinolone drugs on gyrA gene mutation in Mycobacterium tuberculosis. Tuberc Respir Dis. 2005; 59:250–256.

19. Jo KW, Lee SD, Kim WS, Kim DS, Shim TS. Treatment outcomes of ofloxacin-resistant multidrug-resistant tuberculosis depending on moxifloxacin susceptibility. Int J Tuberc Lung Dis. 2013; [In press].

20. Anonymous. Linezolid. Tuberculosis (Edinb). 2008; 88:122–125.

21. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE 3rd. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012; 367:1508–1518.

22. Koh WJ, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, Shim TS. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: Updated analysis of 51 patients. J Antimicrob Chemother. 2012; 67:1503–1507.

23. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2013; 68:284–293.

24. Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trébucq A. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med. 2013; 188:608–612.

25. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182:684–692.

26. Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013; 17:1001–1007.

27. Yoo JW, Lyu J, Lee SD, Kim WS, Kim DS, Shim TS. Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013; 17:1243–1244.

28. Alsaad N, Wilffert B, van Altena R, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW. Potential antimicrobial agents for the treatment of MDR-TB. Eur Respir J. 2013; [In press].

29. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Kim JY, Shim TS. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008; 178:1075–1082.

30. International Union Against Tuberculosis and Lung Disease. Guidelines for clinical and operational management of drug-resistant tuberculosis. 2013.

31. Hwang SS, Kim HR, Kim HJ, Kim MJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. Eur Respir J. 2009; 33:581–585.

32. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Shim TS. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182:113–119.

33. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008; 47:496–502.

34. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007; 45:1290–1295.

35. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009; 360:2397–2405.

36. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012; 366:2151–2160.

37. Clayden P, Collins S, Daniels C, Frick M, Harrington M, Horn T, Jefferys R, Kaplan K, Lessem E, Swan T. 2013 pipeline report: HIV, hepatitis C virus (HCV), and tuberculosis (TB) drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development. London: HIV i-Base;2013.